Global Orphan Drug Market Sales Revenue Opportunity Report 2018

The global pharmaceutical industry has been experiencing a slow growth in recent years owing to many factors such as expiration of patents, competition from generic drugs segment, exhausting pipelines, and an increasingly stringent regulatory framework. It is most likely that many blockbuster drugs would lose their exclusivity in the next 5 year horizon.

Download Report:

https://www.kuickresearch.com/report-Global-Orphan-Drug-Market-Outlook-2018.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"Global Orphan Drug Market Outlook 2018" Table of Contents

1. Introduction to Orphan Drugs
1.1 Orphan Drug Defined
1.2 Rising Popularity of Orphan Drugs

2. Why Shift from Non-Orphan to Orphan Drugs?
2.1 Exhausting Product Pipelines
2.2 Profitability of Orphan Drugs
2.3 Increasing R&D Investment
2.4 Role of Economic Incentives
2.5 Patent Protection & Market Exclusivity

3. Global Orphan Drug Market Outlook
3.1 Market Overview
3.2 Biological & Non-Biological Orphan Drugs
3.3 Therapeutic Segmentation
3.4 Regional Segmentation

4. US Orphan Drug Market Outlook
4.1 Orphan Drug Designation Criteria
4.2 Market Overview
4.3 Reimbursement Policy
4.4 Regulatory Framework

5. Europe Orphan Drug Market Outlook
5.1 Orphan Drug Designation Criteria
5.2 Market Overview
5.3 Reimbursement Policy
5.4 Regulatory Framework

6. Asia Orphan Drug Market Outlook
6.1 Orphan Drug Designation Criteria
6.2 Market Overview
6.3 Reimbursement Policy
6.4 Regulatory Framework

7. Global Orphan Drug Pipeline Insight by Phase, Orphan Designated Disease & Country
7.1 Clinical Phase: Research
7.2 Clinical Phase: Preclinical
7.3 Clinical Phase: Phase I
7.4 Clinical Phase: Phase I/II
7.5 Clinical Phase: Phase II
7.6 Clinical Phase: Phase II/III
7.7 Clinical Phase: Phase III
7.8 Clinical Phase: Preregistration
7.9 Clinical Phase: Registered

8. Key Issue to be Resolved
8.1 High Initial Investment
8.2 Clinical Study Hurdles
8.3 Regulatory Hurdles
8.4 Different Reimbursement Policy
8.5 Distribution Challenges

9. Competitive Landscape
9.1 Pfizer
9.2 Roche
9.3 Sanofi
9.4 Rare Disease Therapeutics
9.5 Glaxosmithkline
9.6 Merck
9.7 Novartis Pharmaceuticals
9.8 Alexion
9.9 Celgene
9.10 Biogen Idec
9.11 Eli Lilly
9.12 Bristol Myers Squibb

Figure 2-1: Orphan v/s Non-Orphan Drugs -Phase II to Launch Clinical Development Time
Figure 2-2: Probability of Regulatory Success of Orphan v/s Non-Orphan Drugs
Figure 3-1: Global Orphan Drugs Market Value (US$ Billion), 2012-2018
Figure 3-2: Biological & Non Biological Orphan Drug Segment (%), 2012 & 2018
Figure 3-3: Biological & Non Biological Orphan Drug Market (US$ Billion), 2012-2018
Figure 3-4: Global Orphan Drugs Market by Therapeutic Area, 2012 & 2018
Figure 3-5: Regional Markets for Orphan Drugs, 2012 & 2018
Figure 4-1: US Market for Orphan Drugs (US$ Billion), 2012-2018
Figure 4-2: US - Orphan Drug Development by Clinical Phase (%)
Figure 4-3: US - Number of Orphan Drug by Clinical Phase
Figure 5-1: European Market for Orphan Drugs (US$ Billion), 2012-2018
Figure 5-2: Europe - Orphan Drug Development by Clinical Phase (%)
Figure 5-3: Europe - Number of Orphan Drug by Clinical Phase
Figure 6-1: Asia- Orphan Drug Development by Clinical Phase (%)
Figure 6-2: Asia - Number of Orphan Drug by Clinical Phase
Figure 6-3: Japan Orphan Drug/Medical Device Designation System
Figure 6-4: Japan Orphan Drug/Device Designation Process
Figure 7-1: Global - Orphan Drug Development by Clinical Phase (%)
Figure 7-2: Global - Number of Orphan Drug by Clinical Phase
Figure 7-3: Global - Number of Orphan Drug by Clinical Phase & Region
Figure 8-1: Orphan Drug Regulatory Hurdles

List of Tables

Table 2-1: Drugs Patent Expiry in 2014
Table 2-2: Drugs Patent Expiry in 2015
Table 2-3: Drugs Patent Expiry in 2016
Table 2-4: Orphan Drugs in the US and their Costs
Table 2-5: Orphan Drugs in the EU and their Costs
Table 2-6: Incentives for the Development of Orphan Drugs
Table 2-7: Orphan Drug Incentives by Country
Table 7-1: Global - Orphan Drugs in Clinical Development Phase: Research
Table 7-2: Global -Orphan Drugs in Clinical Development Phase: Preclinical
Table 7-3: Global - Orphan Drugs in Clinical Development Phase I
Table 7-4: Global - Orphan Drugs in Clinical Development Phase I/II
Table 7-5: Global - Orphan Drugs in Clinical Development Phase II
Table 7-6: Global - Orphan Drugs in Clinical Development Phase II/III
Table 7-7: Global - Orphan Drugs in Clinical Development Phase III
Table 7-8: Global - Orphan Drugs in Clinical Development Phase: Preregistration
Table 7-9: Global - Orphan Drugs in Clinical Development Phase: Registered

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.